Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
153 Leser
Artikel bewerten:
(1)

MainStreetChamber Holdings, Inc. Retains Guttman Associates for Public Relations and Marketing

Finanznachrichten News

LAS VEGAS, NV / ACCESSWIRE / January 13, 2025 / MainStreetChamber Holdings, Inc. (OTC PINK:MSCH), a leading global provider of intellectual property and brand licensing solutions, is proud to announce that it has retained Guttman Associates as its public relations and marketing agency. Guttman Associates, a prominent boutique firm with expertise in corporate, lifestyle, nonprofit, and entertainment PR, has been instrumental in the growth and success of the kathy ireland® brand for three decades.

Known for its deep expertise and vast media connections, Guttman Associates has played a critical role in establishing kathy ireland® as one of the most recognized and trusted brands globally. Under its guidance, the kathy ireland® brand has achieved unparalleled growth, expanding into a diverse portfolio of industries, from fashion to home goods and more.

"We are thrilled to partner with MainStreetChamber Holdings during this pivotal phase of growth," said Rona Menashe, Co-President and Co-CEO of Guttman Associates. "Our experience in building and amplifying iconic brands, including our long-standing work with kathy ireland®, positions us to support MSCH's mission of innovation and expansion."

Susan Madore, Co-President and Co-CEO of Guttman Associates, added, "At Guttman Associates, we pride ourselves on developing customized strategies that not only raise brand visibility but also foster meaningful connections with key stakeholders. We are excited to bring our expertise in corporate and lifestyle PR to this new partnership."

Larry Kozin, Founder and CEO of MainStreetChamber Holdings, said, "Guttman Associates has a proven track record of success in creating global icons and establishing brands as industry leaders. Their dedication and results-driven approach make them the perfect partner for MSCH as we look to elevate our portfolio and expand our reach in the global marketplace."

With a strong track record in corporate PR, Guttman Associates excels at crafting strategic campaigns that resonate with stakeholders across industries, ensuring that MainStreetChamber Holdings' messaging and brand presence continue to make an impactful impression.

About MainStreetChamber Holdings, Inc.
MainStreetChamber Holdings, Inc. (OTC PINK: MSCH) is a leading global provider of intellectual property and brand licensing solutions. The company develops and markets innovative licensing solutions for organizations of all sizes, from startups to established enterprises. Its diverse portfolio includes Advanced Licensing, kathy ireland® Laundry, kathy ireland® Furniture Factory, kathy ireland® Kids, and the MainStreetChamber of Commerce.

About Guttman Associates
Guttman Associates is one of the country's most prominent boutique public relations agencies, specializing in corporate, lifestyle, entertainment and nonprofit PR. With strong relationships across national and local media, the firm has been instrumental in representing celebrities, pop culture icons, and leading brands, including their 30-year partnership with kathy ireland® Worldwide.

Forward-Looking Statements
The foregoing information regarding MainStreetChamber Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's outlook for growth and market expansion, and which can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business may be described in more detail in the Company's periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Larry Kozin, CEO
MainStreetChamber Holdings, Inc.
Tel: +1 (877) 594-7277
info@MSCH.com

Media Contact:
Rona Menashe
Guttman Associates PR & Marketing
Tel: +1 (310) 246-4600
Rona@Guttmanpr.com

SOURCE: MainStreetChamber Holdings, Inc.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.